Oppenheimer has published a research report on United Therapeutics UTHR.
In the report, Oppenheimer wrote, "UTHR will report key ph.III FREEDOM-C2 results for oral treprostinil in combination with PDE5/ERAs for PAH by the end of August. Based on FREEDOM-M/C results, we believe that oral treprostinil will likely demonstrate a significant, 15-20M 6MWD benefit. Our analyses and physician feedback indicate that this outcome, combined with FREEDOM-M, should be sufficient for oral treprostinil's approval and significant adoption."
Oppenheimer rated United Therapeutics an Outperform with a price target of $77.00. United Therapeutics closed Friday at $48.77.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in